Form 4: Boston Scientific EVP and CFO Daniel J. Brennan Executes Stock Options and Sells Shares Under 10b5-1 Plan

Daniel J. Brennan, EVP and CFO of Boston Scientific, exercised stock options and sold shares of common stock on May 22 and 23, 2024, under a pre-established Rule 10b5-1 trading plan.

Summary

• Daniel J. Brennan, the EVP and CFO of Boston Scientific, executed stock options and sold shares of common stock on May 22 and 23, 2024.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.
• On May 22, 2024, Brennan exercised options to acquire 16,863 shares at $24.55, 16,863 shares at $17.26, 15,642 shares at $27.09, and 15,086 shares at $16.31.
• Also on May 22, 2024, Brennan sold 64,454 shares at a weighted average price of $75.9118.
• On May 23, 2024, Brennan sold 47,621 shares at a weighted average price of $75.1125.
• Following these transactions, Brennan directly owns 223,921 shares of Boston Scientific common stock and holds options to acquire additional shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often executed under pre-established trading plans to avoid accusations of insider trading. The use of a 10b5-1 plan suggests that these sales were planned well in advance and not based on any specific non-public information.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are common across the medical device industry.
• Companies like Medtronic, Abbott, and Stryker also utilize stock options as part of their executive compensation packages.
• The use of Rule 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their stock holdings and avoid insider trading concerns.

Stakeholder Impact

• The stock sales could have a minor impact on the stock price, but the existence of a 10b5-1 plan suggests the sales are routine and not based on inside information.

Key Dates